Value-based care will start to transition from being an option to being a requirement, and better data will be needed to improve how care is delivered to patients, said Kim Woofter, executive vice president of strategic alliances and practice innovation at the Advanced Centers for Cancer Care.
Value-based care will start to transition from being an option to being a requirement, and better data will be needed to improve how care is delivered to patients, said Kim Woofter, executive vice president of strategic alliances and practice innovation at the Advanced Centers for Cancer Care.
Transcript (slightly modified)
What changes do you expect to see in the next 5 years in how we use data to deliver care to patients?
The changes I expect to see in the next 5 years is up to this point it was an option if you want to provide value-based care. When I talk about value-based care I’m talking about the continuum, end-of-life management, and NCCN [National Comprehensive Cancer Network] guidelines—actually following a structured path that’s best for the patient and their family. Up to this point again, it’s been an option—it’s something you did because it was the right thing to do.
I think in the future it’s going to be required and it’s not going to be an option. That’s a good thing for the patient, their family, and the healthcare system as a whole, but we’re going to need the data sets and the data analytics, and access to that on all levels—from large practices to very small. It’s going to have to be cost effective or affordable for practices to get their hands on that technology.
That’s what I think is going to be the biggest hurdle coming our way and the biggest change is no longer going to be an option—it’s going to be a requirement.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More